NasdaqCM:VKTXBiotechs
Why Viking Therapeutics (VKTX) Is Up 29.5% After Striking Major Manufacturing Deal for Obesity Drug
Viking Therapeutics recently announced a multi-year manufacturing agreement with CordenPharma to enable commercial production of its obesity drug candidate VK2735, ensuring supply of more than 1 billion oral pills, 100 million autoinjectors, and 100 million vial/syringe units annually, with prepayments of US$150 million through 2028.
This partnership, alongside clinical progress and positive analyst attention, is drawing interest from larger pharmaceutical companies as VK2735 advances...